Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options
Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Novartis Takes Aim At Systemic Mastocytosis With Midostaurin
Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel